ConductScience.org, home

Paper950465

C3 requirements for formation of alternative pathway C5 convertase.

Daha MR and 2 others. J Immunol, 1976. Cited by 107 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. C3 requirements for formation of alternative pathway C5 convertase. Papers, record 950465. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/950465

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
C3 requirements for formation of alternative pathway C5 convertase.
PubMed
Journal
J Immunol
PubMed
Year
1976
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
107
iCite
Relative citation ratio, by iCite
2.51
iCite
Revised in PubMed
2006-11-15
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Daha MRM R
2Fearon DTD T
3Austen KFK F

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Complement C3Major topic
Complement C5Major topic
Complement System ProteinsMajor topic
ErythrocytesMajor topic
Cell Membrane
Esterases
Hemolysis

Source PubMed

Cited by34

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 107 citations.

PMIDTitleJournalYearIn PapersSource
34,948,444Complement System in Alzheimer's Disease.Int J Mol Sci2021https://conductscience.org/library/papers/34948444PubMed
34,705,082The emerging role of complement in neuromuscular disorders.Semin Immunopathol2021https://conductscience.org/library/papers/34705082PubMed
33,687,995Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.Pharmacol Rev2021https://conductscience.org/library/papers/33687995PubMed
32,765,498Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.Front Immunol2020https://conductscience.org/library/papers/32765498PubMed
31,871,188An inhibitor of complement C5 provides structural insights into activation.Proc Natl Acad Sci U S A2020https://conductscience.org/library/papers/31871188PubMed
27,018,802Structural basis for therapeutic inhibition of complement C5.Nat Struct Mol Biol2016https://conductscience.org/library/papers/27018802PubMed
26,335,102Complement Activation in Patients with Focal Segmental Glomerulosclerosis.PLoS One2015https://conductscience.org/library/papers/26335102PubMed
20,304,920Convertase inhibitory properties of Staphylococcal extracellular complement-binding protein.J Biol Chem2010https://conductscience.org/library/papers/20304920PubMed
19,368,894The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb.Structure2009https://conductscience.org/library/papers/19368894PubMed
18,594,868Nephritic factor and recurrence in the renal transplant of membranoproliferative glomerulonephritis type II.Pediatr Nephrol2008https://conductscience.org/library/papers/18594868PubMed
8,398,646Activated C3 (C3b) in the nephritic glomerulus.Pediatr Nephrol1993https://conductscience.org/library/papers/8398646PubMed
8,288,944Properdin: approaching four decades of research.Immunol Res1993https://conductscience.org/library/papers/8288944PubMed
7,259,350Reduction in alternative complement pathway mediated C3 conversion following burn injury.Ann Surg1981https://conductscience.org/library/papers/7259350PubMed
6,950,410Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.Proc Natl Acad Sci U S A1981https://conductscience.org/library/papers/6950410PubMed
6,934,510Evidence for presence of an internal thiolester bond in third component of human complement.Proc Natl Acad Sci U S A1980https://conductscience.org/library/papers/6934510PubMed
6,902,727Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme.J Clin Invest1980https://conductscience.org/library/papers/6902727PubMed
6,863,540Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro.J Clin Invest1983https://conductscience.org/library/papers/6863540PubMed
6,776,531Active site amino acid sequence of human factor D.Proc Natl Acad Sci U S A1980https://conductscience.org/library/papers/6776531PubMed
6,576,376Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.Proc Natl Acad Sci U S A1983https://conductscience.org/library/papers/6576376PubMed
6,447,230Pathopysiological aspects of immune complex diseases. Part II. Phagocytosis, exocytosis, and pathogenic depositions.Klin Wochenschr1980https://conductscience.org/library/papers/6447230PubMed

See all 34 cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
C3718PubTator's text mininghttps://conductscience.org/library/genes/718NCBI Gene
C5727PubTator's text mininghttps://conductscience.org/library/genes/727NCBI Gene
ERVK-3100,862,689PubTator's text mininghttps://conductscience.org/library/genes/100862689NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/950465

GET https://conductscience.org/api/papers/v1/950465/cited_by?page=2